Day One BiopharmaceuticalsDAWN
DAWN
About: Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Employees: 181
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
91% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 22
53% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 45
12% more funds holding
Funds holding: 164 [Q4 2024] → 183 (+19) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0.16% less ownership
Funds ownership: 92.95% [Q4 2024] → 92.79% (-0.16%) [Q1 2025]
30% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $1.76M
37% less capital invested
Capital invested by funds: $1.19B [Q4 2024] → $746M (-$442M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
305%
upside
Avg. target
$30
350%
upside
High target
$36
440%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia | 305%upside $27 | Buy Maintained | 7 May 2025 |
HC Wainwright & Co. Andres Maldonado | 440%upside $36 | Buy Reiterated | 3 Apr 2025 |
Goldman Sachs Andrea Tan | 305%upside $27 | Buy Maintained | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One
Neutral
Seeking Alpha
1 week ago
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301
DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upside, while continued sluggishness risks further stock stagnation or decline. Potential European approval for Ojemda and phase 1 data from a trial of DAY-301 represent other catalysts ahead, but likely won't provide much news this quarter.
Neutral
Seeking Alpha
1 month ago
Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Alec Stranahan - Bank of America Soumit Roy - Jones Research Andrea Newkirk - Goldman Sachs Andres Maldonado - H.C. Wainwright Operator Ladies and gentlemen, thank you for standby.
Negative
Zacks Investment Research
1 month ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif.
Neutral
GlobeNewsWire
1 month ago
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025.
Positive
Seeking Alpha
2 months ago
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity
Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps in part due to a broader biotech sector pullback. A readout from the FIREFLY-2 trial of Ojemda might not be near-term, but does provide the potential for label expansion for those with a few quarters of patience.
Neutral
Seeking Alpha
3 months ago
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Negative
Zacks Investment Research
3 months ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.64 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively
Charts implemented using Lightweight Charts™